About Genedit
Genedit is a Healthcare company based in Berkeley (United States) founded in 2016. Genetic medicines are delivered using polymer nanoparticle platforms. It operates in the Healthcare and Technology sectors. Genedit has raised $93.5 million across 5 funding rounds from investors including Lilly, SK and Korea Investment Holdings. The company has 34 employees. Genedit offers products and services including NanoGalaxy. Its focus areas include Life Sciences, Genomics, Enabling Technologies and Technology Platforms. Its legal entity is GENEDIT INC. Its competitors include Ultragenyx, Alnylam and Gemini Therapeutics; 3 of its 3 listed competitors have raised funding.
Company details
Genedit was founded in 2016 and is headquartered in Berkeley, United States. Operations focus on the biotechnology sector, where non-viral, non-lipid polymer nanoparticles are developed for drug delivery. The NanoGalaxy platform is employed to transport genetic medicines to specific tissues, enabling disease treatment. This approach supports targeted therapies in genetic medicine applications.
- Headquarters Berkeley, United States
- Employees 34
- SectorsHealthcareTechnology
- Email••••••••
- Website genedit.com
- Social X
- Legal Name Genedit Inc
- Total Equity Funding$93.5M (USD)
in 5 rounds
- Latest Funding Round$35M (USD), Series B
Nov 2024
- InvestorsLilly
& 14 more
- Employee Count34
Products & Services of Genedit
Genedit offers a comprehensive portfolio of products and services, including NanoGalaxy.
Enables targeted delivery of genetic medicines for disease treatment.
Funding Insights of Genedit
Genedit has successfully raised a total of $93.5M across 5 strategic funding rounds. The most recent funding activity was a Series B round of $35 million completed in November 2024. This substantial capital infusion reflects strong investor confidence in the company's business model, growth potential, and market opportunities. The funding enables strategic expansion, product development, market penetration, and operational scaling to drive long-term value creation and competitive advantage.
- Total Funding $93.5M
- Total Rounds 5
- Last Round Series B — $35M
- First Round $8.5M
(Dec 2018)
- Investors Count 15
All 5 funding rounds of Genedit with amounts and investors; the two latest post-money valuations are shown, the rest are part of the premium plan.
| Date | Amount | Transaction Name | Valuation | Lead Investors | Investors |
|---|---|---|---|---|---|
| Nov 2024 | $35M | Series B | – | DSC Investment | |
| Jan 2024 | $24M | Series A | – | – | – |
| Sep 2021 | $26M | Series A | – | Lilly, Company K Partners | |
| Feb 2019 | $225,000 | Grant | – | – | |
| Dec 2018 | $8.5M | Seed | – | DCVC, SK |
15 investors in total: 15 institutional.
Investors in Genedit
Genedit has secured backing from 15 investors, including venture fund and institutional investors. Prominent investors backing the company include Lilly, SK and Korea Investment Holdings.
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
Early-stage venture capital is invested primarily in South Korean startups. | 2012 | dscinvestment.com | Seoul, South Korea | |
| woorivp.us | ||||
Investment holding firm established in Seoul in 2003. | 2003 | koreainvestment.com | Seoul, South Korea | |
Venture capital firm investing in tech startups | 2006 | kpartners.co.kr | Seoul, South Korea | |
Stage & sector-agnostic VC firm funding companies in South Korea and the US | 1981 | ktbnetwork.com | Seongnam-si, South Korea | |
Dayli Partners is focused on bio-healthcare and fintech investments. | dayli.partners | Seoul, South Korea | ||
Venture capital fund investing in early-stage tech startups | 1990 | kbic.co.kr | Seoul, South Korea | |
Growth stage companies are targeted for private equity investments. | imm.co.kr | Gangnam, South Korea | ||
Venture capital firm linking startups to University of California networks. | 2020 | bowcapital.com | Menlo Park, United States | |
Sequoia Capital is engaged in venture capital investments. | 1972 | sequoiacap.com |
Investor details for Genedit
The complete investor list, round-by-round participation and investor portfolios require an active premium plan.
- Complete investor list
- Round participation
- Investor portfolios
- Co-investor network
Verified entity values are shown only after access is granted.
People of Genedit
37 people are tracked at Genedit (6 in leadership, 12 in board & advisors, 19 in team); the tracked headcount is 34.
| Name | Role | Group |
|---|---|---|
Kunwoo Lee | Chief Executive Officer & Co-founder | Leadership |
Santanu Maity | Associate Director | Leadership |
Connie Xu | Senior Director, Program Management | Leadership |
Timothy Fong | Chief Technology Officer | Leadership |
Steven Bodovitz | VP Of Corporate Strategy | Leadership |
Derek Sloan | Vice President, Therapeutic Product And Process Development | Leadership |
Kiersten Stead | Board Member | Board & advisors |
Matthew Rabinowitz | Board Member | Board & advisors |
David Schaffer | Advisor | Board & advisors |
Steven Lo | Advisor | Board & advisors |
Jong-Min Lee | Advisor | Board & advisors |
Jiwoong Chun | Director | Board & advisors |
June Lee | Director | Board & advisors |
Jun Yoon | Advisor | Board & advisors |
Thomas Marron | Board Observer | Board & advisors |
George Church | Advisor | Board & advisors |
Josephine Chen | Board Observer | Board & advisors |
Hochan Lee | Board Observer | Board & advisors |
Hyunho Park | Consultant | Team |
Romuald Corbau | Scientific Advisor | Team |
17 more people are available in the full profile.
Complete people profiles for Genedit
Full employee and board profiles, team structure, tenure and professional contact details require an active premium plan.
- Full employee list
- Team structure
- Board tenure
- Professional contacts
Verified entity values are shown only after access is granted.
Timeline of Genedit
3 dated milestones of Genedit across 8 years, from founding to its latest funding, stage changes and deals.
- Founded Genedit is founded.
- Funding First funding round of $8.5M.
- Funding Latest funding round, Series B, of $35.0M.
Competitors of Genedit
Genedit has 3 listed competitors in our database, 3 of them funded. They include Ultragenyx, Alnylam and Gemini Therapeutics.
| Company Name | Domain | Founded | HQ Location | Total funding | Employees | Description |
|---|---|---|---|---|---|---|
| ultragenyx.com | 2010 | Novato, United States | $135.1M | 837 | Therapeutics for rare and ultra-rare metabolic diseases are developed. | |
| alnylam.com | 2002 | Cambridge, United States | $17M | 2,100 | RNA interference-based therapeutics are developed for multiple disorders. | |
| geminitherapeutics.com | 2015 | Cambridge, United States | $44.5M | 45 | Developer of precision therapeutics for dry AMD and rare genetic diseases |
Detailed competitors of Genedit
The full competitor set, operating metrics and side-by-side benchmarks require an active premium plan.
- Full competitor set
- Operating metrics
- Benchmarks
- Competitive positioning
Verified entity values are shown only after access is granted.
Web traffic of Genedit
The website of Genedit (genedit.com) receives about 5.5K visits a month.
- Monthly visits5.5K
▲ 38.1% vs previous month
Top companies in Genomics & Gene Therapy Platforms
3 companies that operate in the same segment as Genedit (Genomics & Gene Therapy Platforms) in United States, ranked by their profile score on The Company Check.
| Company | Description | Founded | Location | Total funding | Revenue | Employees |
|---|---|---|---|---|---|---|
mRNA-based therapeutics for diseases including cancer and infections are developed. | 2010 | Cambridge, Massachusetts, United States | USD 2.78 B | USD 1.94 B | 5,800 | |
Digital sequencing technology for cancer detection is developed. | 2012 | Redwood City, California, United States | USD 557.5 M | USD 982.02 M | 4,867 | |
Circulating tumor DNA is screened for early cancer detection. | 2016 | Menlo Park, California, United States | USD 2 B | USD 147.17 M | 1,141 |
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
Related news about Genedit
Complete news archive for Genedit
Full article history, source details, and older brand coverage require an active premium plan.
- Full article archive
- Source and publication date
- Older coverage
- Brand-specific news history
Verified entity values are shown only after access is granted.
Frequently Asked Questions about Genedit
Genedit was founded in 2016 and raised its 1st funding round 2 years after it was founded.
Genedit is headquartered in Berkeley, United States. It is registered at Berkeley, California, United States.
Genedit is a funded company, having raised a total of $93.5M across 5 funding rounds to date. The company's 1st funding round was a Seed of $8.5M, raised on Dec 2018.
Genedit has 34 employees.
Genedit was founded in 2016 and is headquartered in Berkeley, United States. Operations focus on the biotechnology sector, where non-viral, non-lipid polymer nanoparticles are developed for drug delivery. The NanoGalaxy platform is employed to transport genetic medicines to specific tissues, enabling disease treatment. This approach supports targeted therapies in genetic medicine applications.
Genedit's top competitors include Alnylam, Ultragenyx and Gemini Therapeutics.
Genedit offers NanoGalaxy.
Genedit has 15 investors. Key investors include Lilly, SK, Korea Investment Holdings, DSC Investment, and KB Investment.
Genedit operates through Genedit Inc.